The enzymatic activity of PSMA can be exploited for the design of prodrugs, in which an inactive form of the cytotoxic drug is selectively cleaved and thereby activated only at cells that express PSMA within the tumor microenvironment. Here, FOLH1 is linked to neoplasm.